

CONFIDENTIAL

Rowsley Ltd.

To become a leading healthcare player in Southeast Asia

Presentation
March 2018



Disclaimer

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF THAT JURISDICTION. THIS ANNOUNCEMENT SHALL NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY SECURITIES IN ANY JURISDICTION, INCLUDING IN THE UNITED STATES OR ELSEWHERE.

For the purposes of this disclaimer, this presentation (“Presentation”) shall mean and include the slides herein, the oral presentation of the slides by Rowsley Ltd. (the “Company”) or any person on its behalf, any question and answer session that follows the oral presentation, hard copies of this Presentation and any materials distributed in connection with the Presentation as well as any full or partial copies, extracts or quotes thereof. By attending the meeting at which the Presentation is made, dialing into the teleconference during which the Presentation is made and/or reading the Presentation or any full or partial copies, extracts or quotes thereof, you (the “Recipient”) will be deemed to have agreed to all of the restrictions that apply with regard to the Presentation and acknowledged that you understand the legal regulatory sanctions attached to the misuse, disclosure or improper circulation of the Presentation.

This Presentation does not constitute, and should not be construed as, an offer to sell or issue securities or otherwise constitute an invitation or inducement to any person to purchase, underwrite, subscribe to or otherwise acquire securities in any jurisdiction where such offer or solicitation is unlawful or unauthorised.

This Presentation has been prepared by the Company solely for informational purposes and does not purport to be all-inclusive or to contain all of the information that a person considering the proposed transaction described herein may require to make a full analysis of the matters referred to herein. The information contained in this Presentation has not been subject to any independent audit or review. There can be no assurance that any information contained in this Presentation that is based on estimates or expectations of the Company is or will prove to be accurate.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information contained herein and no reliance should be placed on it. None of the Company, or any of their affiliates, advisers, connected persons or any other person accepts any liability for any loss howsoever arising (in negligence or otherwise), directly or indirectly, from this Presentation or its contents or otherwise arising in connection with this Presentation.

It is the responsibility of each Recipient to satisfy himself as to the full observance of the laws of the relevant jurisdiction in connection with this Presentation and the proposed transaction described herein. Each Recipient acknowledges that neither it nor the Company intends that the Company act or be responsible as a fiduciary to such Recipient, its management, stockholders, creditors or any other person. By accepting and providing this Presentation, each Recipient, the Company, respectively, expressly disclaims any fiduciary relationship and agrees that each Recipient is responsible for making its own independent judgment with respect to the Company and any other matters regarding this Presentation. Any Recipient who is in any doubt about his position should consult his professional adviser in the relevant jurisdiction.

This Presentation is not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident or located in any jurisdiction where such distribution, publication, availability or use would be contrary to any law or regulation of such jurisdiction or which would require any registration or licensing within such jurisdiction. Any failure to comply with these restrictions may constitute a violation of the laws of the relevant jurisdiction. This Presentation must not be acted on or relied on by persons who are not eligible to consider the proposed transaction described herein. Any investment or investment activity to which this Presentation relates is available only to persons eligible to consider the proposed transaction described herein and will be engaged in only with such persons. No securities of the Company or any of its subsidiaries are being, or will be, registered under the Securities Act, or the securities laws of any state of the United States or other jurisdiction and no such securities may be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any applicable state or local securities laws.

All statements other than statements of historical facts included in this Presentation are or may be forward-looking statements. Forward-looking statements include but are not limited to those using words such as “aim”, “seek”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “project”, “plan”, “strategy”, “forecast” and similar expressions or future or conditional verbs such as “will”, “would”, “should”, “could”, “may” and “might”. These statements reflect the Company’s current expectations, beliefs, hopes, intentions or strategies regarding the future and assumptions in light of currently available information. Such forward-looking statements are not guarantees of future performance or events and involve known and unknown risks and uncertainties. Accordingly, actual results, performance or achievements may differ materially from any future results, performance or achievements expected, expressed or implied by such forward-looking statements. Given the risks and uncertainties that may cause the actual future results, performance or achievements to be materially different from those expected, expressed or implied by the forward-looking statements in this Presentation, Recipients should not place undue reliance on such forward-looking statements, and none of the Company, the Company’s Financial Advisers guarantees any future performance or event or undertakes any obligation to update publicly or revise any forward-looking statements

The information contained in this Presentation is provided as of the date hereof and is subject to change without notice.

Acquisition of Sasteria and issuance of warrants by Rowsley

Item	Overview	
Acquiror	Rowsley Ltd (“Rowsley” or “Company”)	
Vendor	Mr Lim Eng Hock	
Acquisition by Rowsley	Proposed Shares Acquisition	The consideration of S\$1,600,000,000 for Sasteria (“Target Group”), which will be satisfied through the issuance and allotment of 21,333,333,334 new Rowsley shares at the issue price of S\$0.075 per share
	Proposed Warrants Acquisition	Rowsley to acquire 597,319,140 warrants in TMC Life Sciences Berhad, to be paid in cash ⁽¹⁾
Issuance of warrants to all existing Rowsley’s shareholders	Bonus Warrants	<ul style="list-style-type: none"> 2 Bonus Warrants⁽²⁾ with an exercise price of S\$0.09 for each existing share Total proceeds of up to S\$853m assuming all 9,476,834,822 Bonus Warrants are exercised
	Piggyback Warrants	<ul style="list-style-type: none"> 1 Piggyback Warrant⁽³⁾ with an exercise price of S\$0.12 for every 1 Bonus Warrant which is exercised Total proceeds of up to S\$1,137m assuming all 9,476,834,822 Piggyback Warrants are exercised
Change of name of the Company	Proposed change of name of the Company from “Rowsley Ltd.” to “Thomson Medical Group Limited” ⁽⁴⁾	
Financial adviser	Credit Suisse (Singapore) Limited	
Independent financial adviser	Provenance Capital Pte. Ltd.	
Valuer	BDO Advisory Pte. Ltd.	

Source: SGX announcement, Rowsley’s circular to shareholders dated 28 February 2018.

(1) The price of the Sale Warrants shall be based on a sum equivalent to the volume weighted average price of TMC Life Sciences Bhd Warrants traded on Bursa Malaysia for the 1-month period immediately preceding the date falling 4 market days prior to the date of the EGM, multiplied by the number of Sale Warrants.

(2) Exercisable during the period commencing from the date of its issue up to the market day immediately preceding the first anniversary of its date of issue.


(3) Exercisable from its date of issue up to the market day immediately preceding the fourth anniversary of the date of issue of the Bonus Warrants. For the avoidance of doubt, not the fourth anniversary of the date of issue of the Piggyback Warrant.

(4) The proposed name change is subject to approval of Rowsley’s shareholders. An application was made to ACRA on 8 December 2017 for the reservation of the name, and the name has been reserved with ACRA until 12 Apr 2018.





Transaction structure overview

Pre-acquisition as at 15 February 2018



Post-acquisition⁽¹⁾



 Listed on the SGX

 Listed on the Bursa Malaysia

Source: Rowsley's circular to shareholders dated 28 February 2018.

(1) Immediately after the Proposed Acquisition and assuming that no Warrants and/or TMC Life Sciences Bhd Warrants are exercised and no TMC Life Sciences Bhd shares are issued pursuant to the exercise of options granted under the TMC Life Sciences Bhd Employee Stock option Scheme.

(2) The proposed name change is subject to approval of Rowsley's shareholders. An application was made to ACRA on 8 December 2017 for the reservation of the name, and the name has been reserved with ACRA until 12 Apr 2018.

(3) Additional 18.43% owned by Vendor through Incanto Investment Ltd and Best Blend Sdn Bhd

Transaction rationale

A

Opportunity to acquire two established healthcare assets in Singapore and Malaysia

- Thomson Medical is the leading private healthcare services provider for women and children
- Tropicana Medical Centre is a multi-disciplinary tertiary care hospital with a comprehensive range of specialties

B

Participate in an expanding healthcare business

- Macroeconomic and demographic trends are expected to drive growth in healthcare spending in the SEA region
- Thomson Medical and TMC Life Science have multiple levers for growth and are well-positioned in their respective markets
- Synergistic opportunities given the development of Thomson Iskandar Medical Hub is located in Rowsley's Vantage Bay Healthcare City development

C

Raise the profile of Rowsley, increase the Company's market capitalisation, and generate investor interest with a sizeable hospital and healthcare platform

- Post-transaction, Rowsley is expected to be one of the largest SGX-listed hospital players in Singapore
- Enhances the corporate profile of the Company and build up its institutional investor base

D


Proceeds from warrants will strengthen balance sheet, fund expansion plans and future working capital

- Warrants provide investors with an opportunity to participate in future upside in the business
- Proceeds from the exercise of the Warrants can be used for working capital and expansion plans, including any strategic acquisitions of further healthcare assets

Opportunity for Rowsley to transform into a healthcare player


Revenue⁽¹⁾⁽²⁾

(in S\$m)




Adjusted EBITDA⁽¹⁾⁽²⁾⁽³⁾

(in S\$m)



Total Assets⁽¹⁾⁽²⁾

(in S\$m)



■ Rowsley's existing business

■ Sasteria and its subsidiaries

Acquisition of Sasteria provides Rowsley with a significant exposure to the healthcare sector

Source: Company filings, SGX announcement.

(1) Based on Rowsley unaudited consolidated last twelve months financials for the financial period ended 30 September 2015, 2016, 2017.


(2) Based on Sasteria consolidated audited full year financial statement for the financial period ended 31 August 2015, 2016, 2017.

(3) Based on Rowsley adjusted EBITDA and Sasteria EBITDA. EBITDA is a non-GAAP measure and refers to earnings before interest, tax, depreciation and amortization. Adjusted EBITDA = Reported EBITDA adjusting for fair value changes in purchase consideration payable, gain on remeasurement of previously held equity interest in an associate which became a subsidiary, impairment loss on investment in an associate, impairment loss on investment in available-for-sale financial assets, impairment loss on goodwill on subsidiaries, impairment loss on property, plant and equipment, impairment loss on investment property and development property.



Allows Rowsley to participate in an expanding healthcare sector

Healthcare expenditure per capita



Through the Proposed Acquisition, the Company would gain access to a platform allowing it to participate in the growth of the healthcare sector

Source: World Health Organization.


Note: Data as of 30 June 2016.

(1) Per capita total expenditure on health expressed at average exchange rate for that year in US\$ in 2014.

(2) 10-year compounded annual growth rate in healthcare expenditure per capita (at average exchange rate in US\$) from 2004 to 2014.

Post-transaction, Rowsley is expected to be one of the largest listed hospital players in Singapore

Market capitalisation of selected hospital players in Southeast Asia (in S\$m)(1)



Source: Bloomberg as at 15 February 2018.

Note: For illustration purposes only. Actual Rowsley's post-acquisition market capitalisation may differ. Exchange rate of S\$1 to MYR 2.9689, S\$1 to THB 23.8818, and S\$1 to IDR 10,330.50.

(1) Market capitalisation calculated based on a sum equivalent to the volume weighted average price of the shares on 15 February 2018, multiplied by the shares outstanding.

(2) Assume all 9,476,834,822 Bonus Warrants are exercised at the Bonus Warrants' exercise price of S\$0.09.

(3) Assume Rowsley's post-acquisition market capitalisation to increase by Share Purchase Considerations of S\$1,600m.



Proceeds from warrants provide funding for future growth

Proceeds from
Bonus Warrants
Up to S\$852.9m⁽¹⁾



Proceeds from
Piggyback Warrants
Up to S\$1,137.2m⁽²⁾



Strategic acquisition of healthcare assets
in Singapore and the region



Development of Thomson Iskandar
Medical Hub



Repayment of bank loans



Working capital

Source: SGX announcement, Rowsley's circular to shareholders dated 28 February 2018.

(1) Up to 9,476,834,822 Bonus Warrants with an exercise price of S\$0.09.

(2) Up to 9,476,834,822 Piggyback Warrants with an exercise price of S\$0.12.



Details of the Target Group




">38 years of experience in women and children's health"



">23 years of operating track record"

Singapore assets: Thomson Medical is the leading private healthcare services provider for women and children



Hospital



- Delivery suite



- Cardiology

Specialty clinics



- Wellth clinic



- Thomson Fertility Centre

Awards



- Delivery



- Single bed ward



- Pediatric clinic




- Women's clinic



Source: Company information.

Singapore assets: Thomson Medical is the leading private healthcare services provider for women and children



LEGEND:

- Women's clinic
- Paediatric's clinic
- Other clinics and centres

Established platform with specialist clinics island wide to serve patients at Thomson Medical Centre, the leading private healthcare services provider for women and children

Source: Company information
 Note: Diagram shown above is for illustration purposes only.

Malaysia assets: TMC Life Sciences has a multi-disciplinary tertiary care hospital and is a leading provider of IVF services



Hospital



- MRI machine



- Suite

Specialty clinics



- Orthopaedic



- Women & Fertility Centre

Awards



Global Health and Travel Awards 2016 and 2017
Fertility Service Provider of the Year



- Catheterization lab



- Dialysis Centre



- ENT




- Specialist Centre



International Fertility Clinic of the Year 2016 and 2017

Malaysia assets: Network of hospital and fertility centres with strong quality accreditations and certifications



TMC Life Sciences plans to expand its hospital network through the expansion at Tropicana Medical Centre and construction of Hospital Iskandariah in Thomson Iskandar Medical Hub

Source: Company information

Note: Diagram shown above is for illustration purposes only. Johor CIQ refers to Johor Bahru Customs, Immigration, and Quarantine Complex.

Multiple growth drivers and initiatives underway to capitalise on the increasing demand for healthcare services in the region



Singapore

Thomson Medical Centre



Current

- 187 licensed beds
- 34 clinics and centres

Expansion plans

- Build an integrated country-wide healthcare network
- Expand current service offerings and open new specialist clinics



Malaysia

Tropicana Medical Centre



- 205 licensed beds
- 6 fertility centres
- Approval obtained to commence construction of 430-bed expansion

- Additional 430 beds with expansion expect to be completed in 2020
- Estimated to cost MYR 450 million and will be funded from existing cash balances, future operating cash flow and debt financing

Thomson Iskandar Medical Hub



- Under development
- Preliminary earth works in respect of the construction of the general hospital have commenced⁽¹⁾

- Development of 500-bed hospital, 400-suite medical tower and complementary retail space, expected to be completed by 2021
- Estimated to cost MYR 1.2 billion and funded from existing cash balances, future operating cash flow, the proceeds from the exercise of TMC Life Sciences Warrants and debt financing

Vantage Bay Healthcare City



- Land bank owned by Rowsley. Book value as of Dec 17: S\$294.8 million
- Lifestyle cluster which includes F&B offerings and a pharmacy managed by TMC Life Sciences

- Vantage Bay Healthcare City will create an integrated healthcare service platform that is unique to the region
- Expansion to be partially funded by proceeds from new Rowsley's warrants

Total number of licensed beds

392 licensed beds

Number of beds to grow by 3.4x


1,322 licensed beds

Source: SGX announcement, Rowsley's circular to shareholders dated 28 February 2018.
 (1) Plan is subjected to further regulatory approval.

A proven track record of operational and financial improvement


Thomson Medical

(S\$ in millions)



TMC Life Sciences

(S\$ in millions)



Financial turnaround

Strategies implemented since Vendor acquired

- Optimized efficiency in Thomson Medical to increase number of medical suites
- Expanded its operations to include new areas of specialties and services
 - Ventured into 34 complementary clinics and centres
- Streamlined operations to remove cost inefficiencies
 - Achieved 2x revenue growth and 12x net profit growth since acquiring controlling stake
- Grow its business beyond its core IVF services
- Ramped up marketing efforts to capture foreign patients as an additional growth driver

Significant value created since acquiring 100% of Thomson Medical Centre and 70% in TMC Life Sciences in 2010 and 2014 respectively

Source: Company filings, Bloomberg.

Note: Exchange rate of S\$1 to MYR 3.000. Thomson Medical FY2010, Thomson Medical FY2017 and TMC Life Sciences FY2017 fiscal year ends 31 Aug. TMC Life Sciences FY2013 fiscal year ends 31 May.





Timing and next steps



">38 years of experience in women and children's health"



">23 years of operating track record"

Indicative timetable

Appoint a proxy to vote on your behalf by returning the duly signed Proxy Form	<u>21 March 2018 at 10.00am</u>
Date and time of EGM (Venue: Holiday Inn Singapore Atrium)	<u>23 March 2018 at 10.00am</u>
Expected last date for Shares to trade cum-rights to the Proposed Bonus Issue of Bonus Warrants and Piggyback Warrants	3 April 2018
Expected date for Shares to trade ex-rights to the Proposed Bonus Issue of Bonus Warrants and Piggyback Warrants	4 April 2018
Expected Books Closure Date and time	6 April 2018 at 5.00 p.m.
Expected Completion (issuance of Consideration Shares) Expected date for issuance of the Bonus Warrants Expected date of suspension of trading of Shares	13 April 2018
Expected date of crediting of Bonus Warrants	16 April 2018
Expected date of commencement of management roadshow and bookbuilding for Placement	16 April 2018 to 27 April 2018
Expected date of pricing and allocation of Placement and announcement of indicative Placement details	27 April 2018
Expected date of settlement and expected completion of Placement and announcement of final Placement details	4 May 2018
Expected date and time of resumption of trading of Shares	7 May 2018 at 9.00 a.m.
Expected date and time for the listing and quotation of the Bonus Warrants on the SGX-ST	7 May 2018 at 9.00 a.m.

Source: Rowsley's circular to shareholders dated 28 February 2018.

Note: Please note that the above timetable is indicative only and may be subject to change. Where any of the events cannot take place on the dates specified, an appropriate announcement stipulating an alternative date will be made by the Company prior thereto through a SGXNET announcement to be posted on the internet at the SGX-ST website, <http://www.sgx.com>.

Summary of approvals sought

Ordinary Resolution 1	Proposed Acquisition and the proposed allotment and issuance of 21,333,333,334 Consideration Shares <i>Contingent on Ordinary Resolution 4</i>
Ordinary Resolution 2	Proposed Bonus Issue of Bonus Warrants <i>Contingent on Ordinary Resolution 1, 3, 4</i>
Ordinary Resolution 3	Proposed Bonus Issue of Piggyback Warrants <i>Contingent on Ordinary Resolution 1, 2, 4</i>
Ordinary Resolution 4	Proposed Whitewash Resolution <i>Contingent on Ordinary Resolution 1</i>
Ordinary Resolution 5	Proposed Appointment of Mr Quek Hong Sheng Roy as a Director <i>Contingent on Ordinary Resolution 1, 4</i>
Ordinary Resolution 6	Proposed Appointment of Mr Heng Kim Chuan Freddie as a Director <i>Contingent on Ordinary Resolution 1, 4</i>
Ordinary Resolution 7	Proposed Share Issue Mandate <i>Contingent on Ordinary Resolution 1, 2, 3, 4</i>
Special Resolution 8	Proposed Adoption of the New Constitution of the Company
Special Resolution 9	Proposed Change of Name

Source: Rowsley's circular to shareholders dated 28 February 2018.

CONFIDENTIAL

End of Presentation
Thank You

